In the half yearly report published in Feb 2019 - "The Company...

In the half yearly report published in Feb 2019 -

"The Company is developing BB-103 for the treatment of HBV. Results of in vivo and in vitro studies, from December2016, March 2016 and December 2015, demonstrated the potential utility of an approach that combines RNAi withgene therapy to treat HBV. In April 2017, the Company completed a pre-IND submission with the FDA in which thefeedback provided by The Agency included details regarding steps required to initiate a clinical trial for BB-103.The Company is seeking partnerships to support the progression of BB-103 into the clinic."

"The senior leadership team will continue to explore partnership opportunities with global pharmaceuticalcompanies, as we expect the unique attributes of the proprietary ddRNAi approach and the breadth ofpotential clinical applications to support the formation of additional collaborations over a broad range ofdisorders with significant unmet medical need."


https://blt.irmau.com/irm/PDF/2063_0/Appendix4DandHalfYearReport